Construction of a National Diagnosis and Treatment Quality Control Platform for Major Respiratory Diseases

Sponsor
China-Japan Friendship Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05687461
Collaborator
(none)
10,000
1
37
270.3

Study Details

Study Description

Brief Summary

  1. Build a national diagnosis and treatment quality control platform for major respiratory diseases It will establish and improved a "National diagnosis and Treatment quality control Platform for major respiratory diseases", and form a three-level network of diagnosis and treatment quality control for major respiratory diseases with a three-level system structure of "national, provincial and hospital".

  2. Promote standardized diagnosis and treatment techniques for major respiratory diseases Relying on the specialized disease collaboration group or innovative unit model, all-round and hierarchical precision training and teaching are carried out to popularize and promote standardized diagnosis and treatment technology schemes for major respiratory diseases, so as to achieve the homogenization of diagnosis and treatment level for major respiratory diseases.

Condition or Disease Intervention/Treatment Phase
  • Other: Build a national diagnosis and treatment quality control platform for major respiratory diseases

Detailed Description

  1. Build a national diagnosis and treatment quality control platform for major respiratory diseases Cooperate with the Medical Administration Administration of the National Health Commission, the Medical Administration Institute of the National Health Commission and the National Center for Respiratory Disease Medical Quality Control to integrate the existing diagnosis and treatment quality indicators and data from NCIS (National Medical Quality Management and Control Information Network) and HQMS (Hospital Quality Monitoring System), and determine the definition, data sources and collection rules of core quality control indicators. It has established and improved a "National diagnosis and Treatment quality control Platform for major respiratory diseases", and formed a three-level network of diagnosis and treatment quality control for major respiratory diseases with a three-level system structure of "national, provincial and hospital".

  2. To master the incidence trend and diagnosis and treatment quality of major respiratory diseases Through the big data integration and analysis function of the "National Diagnosis and Treatment Quality Control Platform for Major Respiratory Diseases", the incidence trend and law of various major respiratory diseases are mastered. To understand the difference in the diagnosis and treatment quality of respiratory diseases in hospitals of different regions and levels, including the allocation of related resources (such as personnel, technology, equipment, information construction, etc.); The status of diagnosis and treatment ability (prevention, diagnosis, treatment, rehabilitation, etc.); Current burden of disease (e.g. morbidity, case fatality rate, average length of stay, average cost of stay, etc.)

  3. Promote standardized diagnosis and treatment techniques for major respiratory diseases Relying on the specialized disease collaboration group or innovative unit model, through online and offline academic conferences, continuing medical education, specialized training, visits and exchanges, case discussions, knowledge competitions, wechat public accounts and other new media means, regularly focus on "prevention, diagnosis, treatment, rehabilitation, management, quality control" and many other aspects. Comprehensive and hierarchical precision training and teaching should be carried out to popularize and promote standardized diagnosis and treatment technology schemes for major respiratory diseases, so as to achieve the homogenization of diagnosis and treatment levels for major respiratory diseases.

Study Design

Study Type:
Observational
Anticipated Enrollment :
10000 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Construction of a National Diagnosis and Treatment Quality Control Platform for Major Respiratory Diseases and Technical Promotion of Standardized Diagnosis and Treatment Programs
Actual Study Start Date :
Jul 1, 2022
Actual Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Jul 31, 2025

Arms and Interventions

Arm Intervention/Treatment
People at high risk for VTE

Patients who are admitted to the hospital for acute medical illness or surgery operations.

Other: Build a national diagnosis and treatment quality control platform for major respiratory diseases
Build a national diagnosis and treatment quality control platform for major respiratory diseases To master the incidence trend and diagnosis and treatment quality of major respiratory diseases Promotion of standardized diagnosis and treatment techniques for major respiratory diseases

People diagnosed with VTE

Patients who were clearly diagnosed with deep vein thrombosis or pulmonary thromboembolism.

Other: Build a national diagnosis and treatment quality control platform for major respiratory diseases
Build a national diagnosis and treatment quality control platform for major respiratory diseases To master the incidence trend and diagnosis and treatment quality of major respiratory diseases Promotion of standardized diagnosis and treatment techniques for major respiratory diseases

Outcome Measures

Primary Outcome Measures

  1. A respiratory quality control network platform has been established [2025.01]

    A complete national quality control network platform for the diagnosis and treatment of major respiratory diseases with multi-source data has been built

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  1. For patients at high risk for VTE 1) Have an expected hospital stay of ≥72 hours for medical and/or surgical treatment II. For patients diagnosed with VTE
  1. With clearly diagnosed of deep vein thrombosis or pulmonary thromboembolism
Exclusion Criteria:
  1. For patients at high risk for VTE
  1. VTE identified on CTPA or lower extremity vein ultrasound at or any time before enrollment

  2. Requiring a full dose of anticoagulant treatment before enrollment (e.g., recent VTE, atrial fibrillation).

Contacts and Locations

Locations

Site City State Country Postal Code
1 China-Japanese Friendship Hosptial Beijing Beijing China 100029

Sponsors and Collaborators

  • China-Japan Friendship Hospital

Investigators

  • Principal Investigator: Zhai Zhenguo, Doctor, Department of Respiratory and Critical Care Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zhenguo Zhai,MD,PhD, Chief physician, China-Japan Friendship Hospital
ClinicalTrials.gov Identifier:
NCT05687461
Other Study ID Numbers:
  • 12100000400014014Y
First Posted:
Jan 18, 2023
Last Update Posted:
Jan 18, 2023
Last Verified:
Jan 1, 2023
Keywords provided by Zhenguo Zhai,MD,PhD, Chief physician, China-Japan Friendship Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 18, 2023